Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Clinical trial NCT04904276 · TERMINATED
Trial details
- NCT number
- NCT04904276
- Sponsor
- Rigel Pharmaceuticals
- Status
- TERMINATED
- Study type
- OBSERVATIONAL
- Start date
- 2021-05-18
- Primary completion
- 2022-11-17
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.